Financial Performance - Total revenue increased 25% to 91.6millionforthethreemonthsendedOctober31,2023,comparedto73.1 million for the same period in 2022[155] - Net loss decreased to 31.9millionforthethreemonthsendedOctober31,2023,fromanetlossof40.2 million in the same period of 2022[155] - Adjusted EBITDA improved to negative 6.6millionforthethreemonthsendedOctober31,2023,comparedtonegative18.3 million for the same period in 2022[155] - Total revenue for the three months ended October 31, 2023, was 91.6million,anincreaseof2573.1 million in the same period in 2022[184] - Total revenue for the nine months ended October 31, 2023, was 261.3million,anincreaseof28204.3 million in the same period in 2022[185] - Adjusted EBITDA for the nine months ended October 31, 2023, was (31,918)thousand,animprovementfrom(74,865) thousand in the same period of 2022[218] Client and Patient Metrics - Average number of healthcare services clients (AHSCs) increased to 3,688 for the three months ended October 31, 2023, from 2,982 in the same period of 2022[169] - Patient payment volume rose to 965millionforthethreemonthsendedOctober31,2023,comparedto815 million for the same period in 2022[171] - Total revenue per AHSC was 24,842forthethreemonthsendedOctober31,2023,up124,515 in the same period last year[184] - Healthcare services revenue per AHSC remained relatively flat at 17,845forthethreemonthsendedOctober31,2023,comparedto17,645 in the prior year[184] Revenue Breakdown - Subscription and related services revenue increased by 9.6millionto42.6 million for the three months ended October 31, 2023, representing a 29% growth year-over-year[186] - Payment processing fees revenue rose by 3.6millionto23.2 million for the three months ended October 31, 2023, an 18% increase compared to the prior year[186] - Network solutions revenue increased by 5.3millionto25.8 million for the three months ended October 31, 2023, a 26% growth year-over-year[186] - Subscription and related services revenue for the nine months ended October 31, 2023, increased by 26.6millionto119.8 million, a 29% growth year-over-year[185] - Payment processing fees for the nine months ended October 31, 2023, increased by 12.5millionto71.1 million, a 21% increase compared to the prior year[193] Expenses - Sales and marketing expense decreased by 0.2millionto36.5 million for the three months ended October 31, 2023, compared to 36.6millionforthesameperiodin2022,primarilyduetoa1.8 million decrease in total compensation and benefits costs[195] - Research and development expense increased by 5.9millionto28.5 million for the three months ended October 31, 2023, representing a 26% increase compared to 22.7millionforthesameperiodin2022[199]−Generalandadministrativeexpenseincreasedby0.6 million to 20.2millionforthethreemonthsendedOctober31,2023,reflectinga319.6 million for the same period in 2022[203] - Sales and marketing expense decreased by 3.9millionto111.1 million for the nine months ended October 31, 2023, a 3% decline from 115.0millionforthesameperiodin2022[197]−Researchanddevelopmentexpenseincreasedby16.6 million to 82.5millionfortheninemonthsendedOctober31,2023,representinga2565.8 million for the same period in 2022[201] - General and administrative expense increased by 0.6millionto61.1 million for the nine months ended October 31, 2023, a 1% increase from 60.5millionforthesameperiodin2022[205]CashFlowandFinancialPosition−Cashandcashequivalentsdecreasedto103.4 million as of October 31, 2023, down 73.3millionfromJanuary31,2023[155]−Freecashflowwasnegative11.6 million for the three months ended October 31, 2023, compared to negative 27.5millionforthesameperiodin2022[155]−FreecashflowfortheninemonthsendedOctober31,2023,was(46,533) thousand, compared to (93,828)thousandforthesameperiodin2022,indicatinga50.529.3 million, a decrease from 74.2millioninthesameperiodof2022[239]−Thecompanybelievesitscashandcashequivalents,alongwithcashgeneratedfromoperations,aresufficienttofundoperationsforatleastthenext12months[232]Acquisitions−ThecompanyacquiredMediFindfor8.9 million on June 30, 2023, to enhance patient-centered care offerings[161] - The acquisition of Access for 37.4milliononAugust11,2023,aimstoimproveworkflowsandpatientexperienceinhospitals[162]−Thecompanyspent14.3 million on acquisitions (MediFind, Access, and ConnectOnCall) during the nine months ended October 31, 2023[241] - The acquisition of ConnectOnCall included liabilities with an acquisition-date fair value of 10,000thousand,payableinsevenquarterlyinstallmentsfromDecember2023throughJune2025[236]DebtandFinancing−Anew5−year50 million senior secured asset-based revolving credit facility was established on December 4, 2023, to enhance financial flexibility[166] - The company entered into a new 5-year $50 million Capital One Credit Facility on December 4, 2023, to replace the terminated Third SVB Facility[229] - As of October 31, 2023, the company had no debt outstanding under the Third SVB Facility and entered into the Capital One Credit Facility on December 4, 2023[255] - The company had no outstanding debt under the Capital One Credit Facility as of the filing date of the report[256] Market Risks and Accounting Policies - The company is exposed to market risks, primarily interest rate and foreign exchange risks, in its operations in the United States and Canada[253] - The company’s estimates and assumptions in financial reporting may differ from actual results, affecting future financial statements and cash flows[250] - There were no significant changes in the company's critical accounting policies and estimates during the three months ended October 31, 2023[251] - During the nine months ended October 31, 2023, there were no significant changes in the company's disclosures about market risk[257] - Changes in interest rates will impact interest expense if the company borrows against the Capital One Credit Facility in the future[256] - The company does not anticipate that a 100 basis point change in interest rates would materially affect its financial condition[254]